Results from a single-center, phase 1, randomized controlled clinical trial show that ocular gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration was found to be safe and well tolerated. The study enrolled patients with wet age-related macular degeneration at the Lions Eye Institute and the Sir Charles Gairdner Hospital in Nedlands, WA, Australia. Eligible
A pioneering trial of a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) has commenced at Moorfields Eye Hospital following a successful operation on a patient.
Patients with active exudative age-related macular degeneration (AMD) are being treated with various treatment regimen, which may include intravitreal ranibizumab (lucentis), bevacizumab (avastin), aflibercept (eylea), etc. Some of these patients do not show benefit from these treatments, including repeat injections in many cases.
A multi-institutional team reports that vitamin D may play a significant role in eye health, specifically in the possible prevention of age-related macular degeneration, or AMD, among women who are more genetically prone to developing the sight-damaging disease. In a paper published in JAMA Ophthalmology online, the team found that women who are deficient in
A team of researchers at the CHA University in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy, which is used to simulate many retinal diseases. The treatment aimed at suppressing abnormal angiogenesis (blood vessel growth) which is recognized
This trip was supported by Allergan Foundation, with instrument support from IRIDEX. Our CEO Dr Raj Agrawal made his second trip to Belize recently. This time, apart from seeing patients in Belize City, he also traveled to Orange Walk, which is an hour’s drive away from Belize City, as well as to Dangriga, which is
A group of researchers from China have evaluated randomized controlled clinical trials from around the world to study the efficacy and safety of Avastintm (bevacizumab) versus Lucentistm (ranibizumab) in wet (neovascular) age-related macular degeneration (AMD).
Scientists from the University of Maryland School of Medicine have found that tiny lumps of calcium phosphate may be an important triggering factor for age-related macular degeneration (AMD). This is the first time these mineral deposits have been implicated in the disease, which affects more than 10 million Americans.